Makes single-use medical devices, including disposable endoscopes, resuscitators and diagnostic equipment.
Makes single-use medical devices, including disposable endoscopes, resuscitators and diagnostic equipment.
Sells disposable devices used once, so hospitals reorder steadily. In endoscopy it sells reusable monitors as equipment and the disposable scopes as the recurring item. Resuscitators are an older, steadier product line.
Moat: narrow (IP / patents, switching costs). Pioneer in single-use endoscopy, reducing cross-infection risk and hospital reprocessing costs.
Headquarters: Ballerup, Denmark · Founded: 1937 · Employees: 5,877
Size Ambu A/S (AMBU-B.CO) is a Denmark Health Care company (Medical Specialties) with a market value of $3.47B, the 25th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 89.20 on 18 Nov 2026.
Performance Over six months the shares gained 30.9%, against -0.4% for the median peer and +6.3% for the Denmark market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 7.2% over the last twelve months (peer median +6.0%); the operating margin is 13.2% (peer median 11.6%).
Valuation It trades at 28.8× forward earnings against a peer median of 23.7× (7th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.3 points above its cost of capital (6.2% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | DKK 6.47B | DKK 6.47B | DKK 6.04B | DKK 5.39B | DKK 4.78B |
| Revenue growth | — | +7% | +12% | +13% | — |
| Gross profit | DKK 3.89B | DKK 3.58B | DKK 3.38B | DKK 2.96B | DKK 2.49B |
| EBITDA | DKK 1.26B | DKK 1.26B | DKK 1.16B | DKK 1.01B | DKK 632M |
| Net income | DKK 642M | DKK 642M | DKK 609M | DKK 235M | DKK 168M |
| Free cash flow | DKK 861M | DKK 861M | DKK 674M | DKK 725M | DKK 447M |
| Capital expenditure | DKK 578M | DKK 578M | DKK 384M | DKK 289M | DKK 326M |
| Total debt | DKK 593M | DKK 593M | DKK 547M | DKK 558M | DKK 584M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Ambu A/S AMBU-B.CO | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% |
| Boston Scientific BSX | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% |
| Olympus 7733.T | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMBU-B.CO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.0% | +3.0% | 4th highest of 21 |
| 6-month return | +30.9% | -0.4% | 7th highest of 21 |
| Distance from 52-week high | -4.3% | -27.7% | 2nd highest of 21 |
| Revenue growth (TTM) | +7.2% | +6.0% | 11th highest of 21 |
| Operating margin | 13.2% | 11.6% | 6th highest of 20 |
| Forward P/E | 28.8× | 23.7× | 7th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 10.0% | 12.5% | 9th least demanding of 18 |
| Growth delivered (Del g) | +10.0% | +8.1% | 8th highest of 18 |
| Hurdle (Req g minus delivered) | -0.0 pp | +1.5 pp | 7th least demanding of 18 |
| ROIC minus cost of capital | +4.3 pp | -1.1 pp | 3rd highest of 19 |
| EV / EBITDA | 18.8× | 12.5× | 4th most expensive of 10 |
| Net debt / EBITDA | 0.1× | 1.0× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Lepu Medical Technology (Beijing) 300003.SZ | China | $3.20B | -13% | -1% | 13% | 24.4× | 8.7% | -4.2% |
| iRhythm IRTC | United States | $3.19B | -19% | +22% | 5% | 99.8× | 46.9% | +23.0% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| Carl Zeiss Meditec AFX.DE | Germany | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% | +10.8% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| MGI Tech 688114.SS | China | $3.06B | -4% | +2% | -7% | n/a | 43.7% | -0.1% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |